Search Our Scientific Publications & Authors

Retin Cases Brief Rep 2020 Jun 26. Epub 2020 Jun 26.

Federal University of São Paulo, São Paulo, Brazil.

Purpose: To report a rare case of subretinal migration of an intravitreal dexamethasone implant to treat macular edema secondary to diabetic retinopathy in a vitrectomized eye and the surgical outcome.

Observations: A pars plana vitrectomy and a retinotomy were performed to remove the implant and restore vision.

Conclusion: and importance: Subretinal dislodgement of intravitreal implants is a rare and preventable complication. Read More

Int J Retina Vitreous 2020 29;6:26. Epub 2020 Jun 29.

Department of Ophthalmology, Centro Hospitalar Universitário de Lisboa Norte, EPE-Hospital de Santa Maria, Avenida Professor Egas Moniz, 1649-035 Lisbon, Portugal.

Background: Diabetic retinopathy (DR) is a leading cause of blindness due to diabetic macular edema (DME) or complications of proliferative diabetic retinopathy (PDR). Optical coherence tomography (OCT) is a noninvasive imaging technique well established for DME but less used to assess neovascularization in PDR. Developments in OCT imaging and the introduction of OCT angiography (OCTA) have shown significant potential in PDR. Read More

Eye (Lond) 2020 Jul 1. Epub 2020 Jul 1.

Medical Retina Consultant, Tilganga Institute of Ophthalmology, Kathmandu, Nepal.

Clin Ophthalmol 2020 22;14:1697-1704. Epub 2020 Jun 22.

The Eye Associates, Sarasota, FL, USA.

Purpose: Calculations of area-under-the-curve (AUC) provide the average letters gained across the entire treatment period, which may be a better estimate of long-term effectiveness than single time-point outcomes, particularly when it comes to sustained-release therapies.

Materials And Methods: The AUC method was used to compare the efficacy of the 0.2 µg/day fluocinolone acetonide (total dose of 0. Read More

Clin Ophthalmol 2020 17;14:1629-1639. Epub 2020 Jun 17.

Genentech, Inc., South San Francisco, CA, USA.

Purpose: To investigate the predictors of early diabetic retinopathy (DR) improvement in the RIDE/RISE (NCT00473382/NCT00473330) clinical trials.

Patients And Methods: In RIDE/RISE, adult patients with vision loss due to diabetic macular edema (DME) were randomized to monthly intravitreal ranibizumab 0.3 or 0. Read More

Clin Ophthalmol 2020 16;14:1609-1618. Epub 2020 Jun 16.

Department of Ophthalmology, Wonkwang University College of Medicine, Iksan, Korea.

Purpose: To analyze the effects on microaneurysm (MA) and perifoveal perfusion in nonproliferative diabetic retinopathy (NPDR) patients with macular edema (ME) after early intensive treatment using intravitreal ranibizumab (IVR) injections.

Patients And Methods: Prospectively, 25 eyes of 25 type 2 diabetes mellitus patients with ME were included between August 2016 and February 2019. For 6 months, patients were administered 0. Read More

J Diabetes Complications 2020 May 30:107641. Epub 2020 May 30.

Department of Ophthalmology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, P.R. China.

Aims: To determine the associations between the levels of certain cytokines in the aqueous humor and the severity of diabetic retinopathy.

Methods: A total of 103 patients (one eye per patient) who received intravitreal injection with ranibizumab for diabetic retinopathy were enrolled and divided into 3 groups: nonproliferative diabetic retinopathy (NPDR) with macular edema group (42 eyes), proliferative diabetic retinopathy (PDR) group (40 eyes) and neovascular glaucoma due to PDR (NVG-PDR) group (21 eyes). The concentrations of interleukin (IL)-6, IL-8, IL-10, vascular endothelial growth factor (VEGF), transforming growth factor-β (TGF-β), vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1), and monocyte chemoattractant protein-1 (MCP-1) in the aqueous humor were measured. Read More

J Xray Sci Technol 2020 Jun 22. Epub 2020 Jun 22.

Department of Electronics Engineering, MIT Campus, Anna University, Chennai, India.

Human eye is affected by the different eye diseases including choroidal neovascularization (CNV), diabetic macular edema (DME) and age-related macular degeneration (AMD). This work aims to design an artificial intelligence (AI) based clinical decision support system for eye disease detection and classification to assist the ophthalmologists more effectively detecting and classifying CNV, DME and drusen by using the Optical Coherence Tomography (OCT) images depicting different tissues. The methodology used for designing this system involves different deep learning convolutional neural network (CNN) models and long short-term memory networks (LSTM). Read More

J Ocul Pharmacol Ther 2020 Jun 24. Epub 2020 Jun 24.

Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Canada.

To investigate the changes in aqueous humor cytokine levels in response to short-term aflibercept therapy in treatment-naive patients with center-involving diabetic macular edema (DME). This is a prospective cohort study that included patients with treatment-naive DME with central subfield macular thickness ≥310 μm on optical coherence tomography from July 2015 to May 2017. Patients received 3 monthly intravitreal aflibercept injections. Read More

Acta Ophthalmol 2020 Jun 26. Epub 2020 Jun 26.

Department of Ophthalmology, Croix-Rousse University Hospital, Hospices Civils de Lyon, University of Medicine Lyon 1, Lyon, France.

JAMA Ophthalmol 2020 Jun 25. Epub 2020 Jun 25.

Doheny Image Reading Center, Doheny Eye Institute, Los Angeles, California.

Importance: Although previous studies have evaluated the association between anti-vascular endothelial growth factor therapy and macular vessel density, they were confounded by the presence of macular edema, which may be associated with artifacts and segmentation errors in optical coherence tomography angiography (OCTA).

Objective: To evaluate the association of intravitreal aflibercept with changes in macular vascular density using OCTA in patients with proliferative diabetic retinopathy without diabetic macular edema.

Design, Setting, And Participants: This post hoc analysis of a randomized clinical trial used data on 40 eyes of 40 patients with proliferative diabetic retinopathy without diabetic macular edema who were enrolled in the Intravitreal Aflibercept for Retinal Nonperfusion in Proliferative Diabetic Retinopathy (RECOVERY) clinical trial from August 1, 2016, to June 31, 2017. Read More

Adv Exp Med Biol 2020 Jun 25. Epub 2020 Jun 25.

Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Research Center, Stockholm, Sweden.

The number of people living with diabetes, the number of deaths attributable to it, and the cost of treating the disease and its complications are increasing exponentially. Centuries of research led to the discovery of insulin and other drugs based on pathophysiology from "the triumvirate to ominous octet". The agonists of the glucagon-like peptide-1 (GLP-1) receptor, and the inhibitors of the sodium-glucose transport protein 2 (SGLT2) are the new drugs that improve cardiovascular outcomes and provide renal protection, and they are being used increasingly for evidence-based treatment of type 2 diabetes. Read More

Am J Ophthalmol Case Rep 2020 Sep 12;19:100775. Epub 2020 Jun 12.

Illinois Retina Associates, Chicago, IL, USA.

Purpose: To report on the technique of scleral fixation of fluocinolone acetonide (FAc) implant in 2 eyes with recalcitrant diabetic macular edema (DME).

Observations: Two eyes of 2 patients with persistent DME, partially responsive to anti-VEGF therapy, underwent intravitreal FAc implant injection. First case had a history of pars plana vitrectomy (PPV) and scleral fixated posterior chamber intraocular lens implant (PCIOL) for retained lens fragments and dislocated IOL. Read More

Int Ophthalmol Clin 2020 ;60(3):41-50

Am J Ophthalmol 2020 Jun 20. Epub 2020 Jun 20.

New England Eye Center, 260 Tremont Street, Boston, MA. Electronic address:

Purpose: To identify optical coherence tomography angiography (OCTA) derived vessel metrics of the macula and optic nerve head (ONH) that predict diabetic retinopathy (DR) disease progression.

Design: Secondary analysis of clinical trial data METHODS: This was a sub-analysis of prospectively collected data from 73 subjects that participated in the TIME-2b Study (Aerpio Pharmaceuticals), a multi-center clinical trial for patients with moderate to severe DR treated with AKB-9778 and followed over a 12-month period. Eligible subjects were tested every 3 months with color fundus photography, spectral domain OCT and slit-lamp biomicroscopy. Read More

Medicine (Baltimore) 2020 Jun;99(25):e20306

Internal Medicine, Griffin Hospital, CT, USA.

Objective: To determine cost-effectiveness and the diagnostic accuracy of teleophthalmology (TO) in the detection of macular edema (ME) and various grades of diabetic retinopathy (DR).

Methods: MEDLINE, EMBASE, and Cochrane databases were searched for TO, ME, and DR on May 25, 2016. The search was updated on April 2, 2019. Read More

Acta Ophthalmol 2020 Jun 22. Epub 2020 Jun 22.

Intelligent Diabetes, Metabolism and Exercise Center, China Medical University Hospital, Taichung, Taiwan.

Purpose: To investigate the time-sequential correlations between progression/remission of diabetic kidney disease (DKD) and development of diabetic retinopathy (DR) or diabetic macular oedema (DME) in type 2 diabetes (T2D).

Methods: This was an 8-year prospective cohort study in which 576 patients with T2D and microalbuminuria from one medical centre in Taiwan were recruited. Progression of microalbuminuria was defined as shift of urinary albumin/creatinine ratio (ACR) into 300 mg/g or more; remission of microalbuminuria was defined as having a urinary ACR less than 30 mg/g in at least two of three tests over a period of 6 months. Read More

J Diabetes Res 2020 25;2020:2450781. Epub 2020 May 25.

Department of Ophthalmology, University of Ulm, Prittwitzstrasse 43, 89075 Ulm, Germany.

Inhibitors of dipeptidyl peptidase-4 (DPP-4) are widely used to treat diabetes mellitus, but data concerning their effects on the barrier stability of retinal endothelial cells (REC) in vivo and in vitro are inconsistent. Therefore, we studied whether the barrier properties of immortalized endothelial cells of the bovine retina (iBREC) were affected by the inhibitors of DPP-4 sitagliptin (10-1000 nM) and diprotin A (1-25 M). Their effects were also investigated in the presence of VEGF-A because diabetic patients often develop macular edema caused by VEGF-A-induced permeability of REC. Read More

Int J Ophthalmol 2020 18;13(6):946-951. Epub 2020 Jun 18.

Department of Ophthalmology, National Taiwan University Hospital, Taipei 10002, Taiwan, China.

Aim: To evaluate and compare the incidences of ocular hypertension and severe intraocular pressure (IOP) elevation after posterior subtenon injection of triamcinolone acetonide (PSTA) for various diseases.

Methods: Totally 179 eyes that had received PSTA for diabetic macular edema (=108), pseudophakic cystoid macular edema (=20), branch retinal vein occlusion (=16), central retinal vein occlusion (CRVO, =14), choroidal neovascularization (=14) or noninfectious uveitis (=7) were retrospectively enrolled. The primary outcomes included ocular hypertension defined as an IOP>21 mm Hg, and severe IOP elevation defined as a rise of 10 mm Hg or more in IOP compared with baseline. Read More

Ophthalmic Res 2020 Jun 19. Epub 2020 Jun 19.

Purpose: The purpose of this study is to investigate retinal layers' changes in patients with diabetic macular edema (DME) treated with anti-vascular endothelial growth factor (anti-VEGF) agents and to evaluate if these changes may affect treatment response.

Methods: Participants in this prospective study were 110 treatment-naïve patients with center involved DME, who were treated with anti-VEGF agents and followed-up for at least 12 months. A qualitative and quantitative analysis of retinal layers that can affect visual acuity was performed. Read More

J Digit Imaging 2020 Jun 19. Epub 2020 Jun 19.

Department of Computer Science and Information Technology, University of A Coruña, 15071, A Coruña, Spain.

The automatic identification and segmentation of edemas associated with diabetic macular edema (DME) constitutes a crucial ophthalmological issue as they provide useful information for the evaluation of the disease severity. According to clinical knowledge, the DME disorder can be categorized into three main pathological types: serous retinal detachment (SRD), cystoid macular edema (CME), and diffuse retinal thickening (DRT). The implementation of computational systems for their automatic extraction and characterization may help the clinicians in their daily clinical practice, adjusting the diagnosis and therapies and consequently the life quality of the patients. Read More

Diagnostics (Basel) 2020 Jun 17;10(6). Epub 2020 Jun 17.

Institute of Ophthalmology, Department of Biomedical Sciences, University of Messina, 98124 Messina, Italy.

Background: The aim of this study was to compare the therapeutic effect of intravitreal treatment with ranibizumab and dexamethasone using specific swept-source optical coherence tomography retinal biomarkers in patients with diabetic macular edema (DME).

Methods: 156 treatment-naïve patients with DME were divided in two groups: 75 patients received 3 monthly intravitreal injections of ranibizumab 0.5 mg (Lucentis) (Group 1) and 81 patients received an intravitreal implant of dexamethasone 0. Read More

Ther Adv Ophthalmol 2020 Jan-Dec;12:2515841420917768. Epub 2020 May 22.

Department of Ophthalmology of Hospital Pedro Hispano, Matosinhos, Portugal.

Introduction: The ILUVIEN (fluocinolone acetonide) Clinical Evidence in Portugal (ICE-PT) study is a retrospective, multicenter, observational study evaluating the effectiveness and safety of the FAc implant in patients with diabetic macular edema.

Methods: Patients included in this study had received the 0.2 µg/day fluocinolone acetonide implant for the treatment of diabetic macular edema and had measurements of visual acuity and retinal thickness assessed by optical coherence tomography for at least 12 months pre- and post-fluocinolone acetonide implant administration, with ⩾2 follow-up visits. Read More

Diabetes Metab Syndr Obes 2020 22;13:1803-1812. Epub 2020 May 22.

Department of Ophthalmology, The First Hospital of China Medical University, Shenyang 110001, People's Republic of China.

Background: To investigate the association between serum carbohydrate antigen 125 (CA125) and the presence as well as severity of diabetes retinopathy (DR) in Chinese adult patients with type 2 diabetes.

Methods: A hospital-based cross-sectional study was conducted from February 2012 to November 2018. DR was assessed using Early Treatment Diabetic Retinopathy Study criteria. Read More

Clin Ophthalmol 2020 25;14:1417-1426. Epub 2020 May 25.

Ophthalmological Clinic, University Hospital of Heraklion, Heraklion, Greece.

Purpose: This multicenter, epidemiological, cross-sectional study aimed to estimate the annual cumulative incidence of major macular diseases that cause visual impairment and require therapeutic intervention in the routine care of Greece.

Methods: The study was carried out between December 2012 and May 2015 in 20 ophthalmology clinics. Over a one-year recruitment period per study site, all treatment naïve adult patients newly diagnosed with wet age-related macular degeneration, visual impairment due to diabetic macular edema or macular edema secondary to retinal vein occlusion requiring therapeutic management and who had not been diagnosed or treated for the same disease in the past were enrolled after providing informed consent. Read More

Diabetes Ther 2020 Jun 15. Epub 2020 Jun 15.

Department of Endocrinology, Hematology and Gerontology, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba, Chiba, 260-8677, Japan.

Introduction: Diabetic macular edema (DME) threatens daily life activities such as reading and driving and reduces the patients' quality-of-life. Recently, anti-vascular endothelial growth factor (VEGF) agents have become a first-line therapy in DME. However, therapy with anti-VEGF agents has several problems: repeated invasive injections are required; medical costs are high; and a certain proportion of patients with DME are resistant to treatment with anti-VEGF agents. Read More

BMC Ophthalmol 2020 Jun 15;20(1):229. Epub 2020 Jun 15.

State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, 54 South Xianlie Road, Guangzhou, 510060, China.

Background: To evaluate the anatomical and functional responses in eyes with diabetic macular edema (DME) treated with ranibizumab under "1 + pro re nata (PRN)" regimen.

Methods: This prospective interventional case series included 69 eyes of 69 patients with DME treated with intravitreal injections of 0.5 mg ranibizumab followed by repeated injections as needed. Read More

Eur J Ophthalmol 2020 Jun 12:1120672120922444. Epub 2020 Jun 12.

Vitreo-Retinal Division, Department of Ophthalmology, Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia.

Purpose: We aimed to perform a systematic literature search on the latest evidence of the role of statin in reducing diabetic retinopathy and its need for intervention.

Methods: A comprehensive search on cohort studies/clinical trials that assess statins and diabetic retinopathy up until August 2019 was performed. The outcome measured was the incidence of diabetic retinopathy and its need for intervention. Read More

Int J Retina Vitreous 2020 8;6:17. Epub 2020 Jun 8.

New England Eye Center, Tufts Medical Center, Tufts University, Boston, MA USA.

Background: To compare the anatomical and visual outcomes in eyes with persistent diabetic macular edema (DME) after initial anti-VEGF therapy that were retreated continuously with the same anti-VEGF drug versus those that underwent two successive cycles of medication change in anti-VEGF drugs (double anti-VEGF switch).

Methods: Retrospective review of eyes with persistent DME after 3 initial consecutive monthly anti-VEGF injections. This cohort was divided into two groups: Group 1 continued to receive the same initial anti-VEGF drug for at least 18 months while group 2 eyes were switched to different anti-VEGF medications twice. Read More

J Chin Med Assoc 2020 Jun 9. Epub 2020 Jun 9.

Department of Ophthalmology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.

Artificial intelligence (AI) has been widely applied in the medical field and achieved enormous milestones in helping specialists to make diagnosis and remedy decisions, particularly in the field of eye diseases and ophthalmic screening. With the development of AI-based systems, the enormous hardware and software resources are required for optimal performance. In reality, there are many places on the planet where such resources are highly limited. Read More

Eur J Ophthalmol 2020 Jun 9:1120672120929639. Epub 2020 Jun 9.

Nuestra Senora de la Candelaria University Hospital, Santa Cruz de Tenerife, Spain.

Eye Vis (Lond) 2020 1;7:29. Epub 2020 Jun 1.

Department of Ophthalmology, New England Eye Center, Tufts Medical Center, 800 Washington Street, Box 450, Boston, MA 02111 USA.

Background: To examine the baseline morphological characteristics and alterations in intraretinal microvascular abnormalities (IRMAs) in response to anti-vascular endothelial growth factor (anti-VEGF) treatment, documented by optical coherence tomography angiography (OCTA) in diabetic eyes.

Methods: In this retrospective study, IRMAs were evaluated with multimodal imaging (fundus photography, fluorescein angiography, OCTA) in treatment-naïve diabetic eyes before and after anti-VEGF treatment for diabetic macular edema (DME) and/or proliferative diabetic retinopathy (PDR) and compared to diabetic control eyes with similar diabetic retinopathy (DR) severity that did not receive anti-VEGF therapy. The morphological characteristics of IRMAs on enface OCTA imaging were graded by masked readers at baseline, then after anti-VEGF therapy in treated eyes or after observation in control eyes. Read More

Ophthalmol Retina 2020 Jun 5. Epub 2020 Jun 5.

Genentech, Inc., South San Francisco, California.

Ophthalmic Surg Lasers Imaging Retina 2020 05;51(5):298-306

Background And Objective: Assess fluocinolone acetonide implant (FAc) effects on diabetic macular edema (DME) retinal thickness fluctuations.

Patients And Methods: A post-hoc chart review of the real-world USER study analyzed patients receiving 0.2 μg/day FAc implant. Read More

Eur J Ophthalmol 2020 Jun 8:1120672120930603. Epub 2020 Jun 8.

Institut de Neurosciences de la Timone, Aix-Marseille University, Marseille, France.

Purpose: To compare the efficacy of intravitreal injections (IVI) of ranibizumab (Lucentis, Novartis, Basel, Switzerland; RAN), aflibercept (Eylea, Bayer, Leverkusen, Germany; AFL) and dexamethasone implant (Ozurdex, Allergan, Irvine, California; DXI) in the treatment of naive diabetic macular oedema (DME) during a 12-month follow-up, in real life.

Methods: Nineteen eyes treated with RAN, 20 with AFL and 21 with DXI were analysed from inclusion up to 12 months (M12) with intermediate analysis at M6. Best corrected visual acuity (BCVA), fundus and central retinal thickness (CRT) using spectral-domain optical coherence tomography (SD-OCT; Spectralis/HRA, Heidelberg Engineering, Germany) were performed at inclusion, M3, M6 and M12. Read More

Eur J Endocrinol 2020 Jun;183(1):41-49

Department of Endocrinology, Key Laboratory of Endocrinology of National Health Commission, PUMCH, CAMS & PUMC, Beijing, China.

Objective: Automatic diabetic retinopathy screening system based on neural networks has been used to detect diabetic retinopathy (DR). However, there is no quantitative synthesis of performance of these methods. We aimed to estimate the sensitivity and specificity of neural networks in DR grading. Read More

Rev Med Liege 2020 May;75(5-6):432-439

Service d'Ophtalmologie, CHU Liège, Belgique.

Diabetic retinopathy is a public health issue and the leading cause of blindness in adults in industrialized countries. Many advances have been made during the last few years in the diagnosis, the understanding of the pathophysiology and the treatment of diabetic retinopathy, especially with the rise of anti-angiogenic treatments. We bring here an overview of the last advances, the current therapeutic algorithms and future perspectives. Read More

Eur J Ophthalmol 2020 Jun 3:1120672120929960. Epub 2020 Jun 3.

Puerta de Hierro Majadahonda University Hospital, Madrid, Spain.

Purpose: To assess the functional and anatomical outcomes of intravitreal dexamethasone implant Ozurdex® in eyes with diabetic macular edema that did not adequately respond to vascular endothelial growth factor inhibitors.

Methods: Multicenter, retrospective, and real-life case series study conducted on consecutive diabetic macular edema patients who underwent treatment with one or more dexamethasone implant injections and were followed up for a minimum of 12 months. Subjects were divided into three groups: I-naïve patients, II-previously treated eyes that received three intravitreal antivascular endothelial growth factor inhibitors injections before the study (early switch), and III-previously treated eyes that received >3 intravitreal antivascular endothelial growth factor inhibitors injections before the study (late switch). Read More

PLoS One 2020 3;15(6):e0233595. Epub 2020 Jun 3.

Department of Ophthalmology and Optometry, Medical University of Vienna, Vienna, Austria.

Purpose: To assess the one-year effectiveness and safety of ranibizumab 0.5 mg in treatment- naïve patients with diabetic macular edema (DME) enrolled in the real-world LUMINOUS study.

Patients And Methods: A 5-year, prospective, observational, open-label, global study which recruited 30,138 patients across all approved indications. Read More

Arq Bras Oftalmol 2020 06 29;83(3):242-245. Epub 2020 May 29.

Department of Ophthalmology, School of Medicine, Afyon University of Health Sciences, Afyonkarahisar, Turkey.

This report describes the therapeutic effects and outcomes of an accidental injection of an intralenticular sustained-release dexamethasone implant (Ozurdex®) in three patients with diabetic macular edema. All three patients underwent accidental injections of sustained-release intravitreal dexamethasone implants into the crystalline lens by the same surgeon. After the accidental injection of Ozurdex® into the crystalline lens, a remarkable reduction in the macular edema and an improvement in visual acuity were observed, suggesting that a positive outcome can be achieved without immediate surgery. Read More

Adv Exp Med Biol 2020 Jun 3. Epub 2020 Jun 3.

Sant' Orsola Malpighi Hospital, Bologna, Italy.

Diabetic macular edema (DME) is the main cause of vision loss in diabetic retinopathy (DR). Although it is one of the main complications of diabetes, the pathogenesis of DME is not completely understood. The hyperglycemic state promotes the activation of multiple interlinked pathways leading to DME. Read More

J Formos Med Assoc 2020 May 29. Epub 2020 May 29.

Department of Ophthalmology, Far Eastern Memorial Hospital, New Taipei City, Taiwan; Department of Medicine, National Taiwan University, Taipei City, Taiwan.

Background/purpose: Vitrectomy may affect intravitreal drug clearance and efficacy for treating diabetic macular edema (DME). This study aimed to evaluate functional and anatomical outcomes of intravitreal dexamethasone (DEX) implant for vitrectomized and nonvitrectomized eyes with treatment-naïve DME in Taiwanese patients.

Methods: In this retrospective single-center study, we reviewed treatment-naïve patients who received DEX implant monotherapy for center-involved DME from January 2015 to May 2017. Read More

Am J Ophthalmol 2020 May 29. Epub 2020 May 29.

Vitreoretinal Service, Moorfields Eye Hospital, London, United Kingdom. Electronic address:

Purpose: To provide data on VA outcomes and prognostic factors of micro-incision 23-gauge vitrectomy (MIVS) for retained lens fragments after complicated cataract surgery.

Design: Retrospective, interventional case series from 2012 to 2017.

Methods: Pre-cataract surgery and intra-operative (vitrectomy) parameters, post-vitrectomy complications, and best-corrected visual acuities (BCVA), were identified. Read More

BMJ Open Diabetes Res Care 2020 May;8(1)

Diabetology, Madras Diabetes Research Foundation and Dr. Mohan's Diabetes Specialities Centre, Chennai, Tamil Nadu, India

Introduction: Previous epidemiological studies have reported on the prevalence of diabetic kidney disease (DKD) and diabetic retinopathy (DR) from India. The aim of this study is to evaluate the effect of DKD on the development of new-onset DR and sight-threatening diabetic retinopathy (STDR) in Asian Indians with type 2 diabetes (T2D).

Research Design And Methods: The study was done on anonymized electronic medical record data of people with T2D who had undergone screening for DR and renal work-up as part of routine follow-up at a tertiary care diabetes center in Chennai, South India. Read More

J Fr Ophtalmol 2020 May 27. Epub 2020 May 27.

The Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia.

Purpose: To evaluate the efficacy of intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections (IVT) in diabetic macular edema (DME) in real-life practice using the Save Sight Registries (SSR).

Material And Methods: We conducted an observational, single-centre, retrospective study in the department of ophthalmology of the Dijon University Hospital. We included treatment-naive patients who presented with DME between January 2016 and December 2017. Read More

Int Ophthalmol 2020 May 29. Epub 2020 May 29.

Ankara Ulucanlar Eye Education and Research Hospital, University of Health Sciences, Ankara, Turkey.

Purpose: To evaluate the effects of epiretinal membrane (ERM) formation on the anatomic and functional results of subjects with diabetic macular edema (DME) who are receiving intravitreal aflibercept injections (IAIs).

Materials And Methods: This retrospective comparative study includes 29 eyes with DME (Group 1) and 43 eyes with DME and ERM (Group 2). After three consecutive monthly 2. Read More

Acta Diabetol 2020 May 29. Epub 2020 May 29.

2nd Department of Ophthalmology, National and Kapodistrian University of Athens, Athens, Greece.

Aims: To compare intravitreal ranibizumab as monotherapy or in combination with panretinal photocoagulation (PRP) in patients with proliferative diabetic retinopathy (PDR) and coexistent diabetic macular edema (DME) in a long-term follow-up of 24 months.

Methods: Participants in this prospective study were 47 patients with PDR and concurrent DME, who were randomized at baseline into two groups: (i) the "ranibizumab alone" group (n = 23), which was treated with at least 3 intravitreal ranibizumab injections as a loading phase, and (ii) the "combination" group (n = 24), which was treated with PRP and at least 3 intravitreal ranibizumab injections. Thereafter, all patients were followed up at a pro re nata (PRN) basis, with regular monthly monitoring for 24 months. Read More

J Ocul Pharmacol Ther 2020 May 27. Epub 2020 May 27.

Department of Ophthalmology, Faculty of Medicine, Baskent University, Ankara, Turkey.

This study aims to compare subfoveal choroidal thicknesses (SFCTs) after intravitreal dexamethasone (IVD) or intravitreal aflibercept (IVA) treatment in patients with persistent diabetic macular edema (DME) unresponsive to intravitreal ranibizumab (IVR). The study consisted of patients with DME unresponsive to IVR treatment in which 37 were administered 1 dose IVD (group A) and 34 patients who were administered 3 doses of IVA (group B), as well as 35 healthy individuals (group C). Detailed ophthalmological examination and optical coherence tomography parameters of group A and group B, including central retinal thickness and SFCT, were retrospectively evaluated before and after treatment. Read More

Sr Care Pharm 2020 Jun;35(6):266-272

To educate pharmacists on advancements in, detection of, and access to care for diabetic eye disease (DED) by reviewing the etiologies, treatment options, and technological evolution in teleophthalmology for DED.
The literature included review articles, original research articles, treatment information, and advancements in teleophthalmology for DED.
DED encompasses a group of eye conditions that affect people with diabetes, which primarily includes diabetic retinopathy and diabetic macular edema but may also include cataracts, ocular surface disease, and glaucoma. Read More

Ophthalmic Res 2020 May 26. Epub 2020 May 26.

Purpose: Correlations among the aqueous flare value (an indicator of inflammation), several functional-morphologic parameters, and aqueous humor levels of multiple cytokines or inflammatory factors were investigated in patients with diabetic macular edema (DME) receiving intravitreal ranibizumab injection (IRI).

Methods: Aqueous humor levels of 12 cytokines, growth factors, or inflammatory factors were measured in 46 DME patients who received IRI. Vascular endothelial growth factor (VEGF), soluble VEGF receptor (sVEGFR), and the other cytokines/inflammatory factors were measured by the suspension array method. Read More